U.S. Market for Blood-Based Parkinson’s Biomarkers Forecast to Hit USD 1.16 Billion by 2034 at 19.6% CAGR
U.S. Market for Blood-Based Parkinson’s Biomarkers Forecast to Hit USD 1.16 Billion by 2034 at 19.6% CAGR
Market Overview
TheU.S. blood-based biomarker for Parkinsons disease marketwas valued atUSD 194.41 million in 2024and is projected to grow significantly to reachUSD 1,156.34 million by 2034, registering acompound annual growth rate (CAGR) of 19.6%during the forecast period from 2025 to 2034. This exponential growth reflects the increasing demand for minimally invasive, accurate, and early diagnostic tools that can aid in identifying Parkinsons disease (PD) at the prodromal or preclinical stage.
These blood tests offer anon-invasive, fast, and scalableway to detect Parkinsons disease earlylong before traditional symptoms fully appear. As a result, they are gaining attention in bothclinical settingsandresearch labsfor early diagnosis, monitoring disease progression, and helping in drug development.
Whats Driving the Growth?
- Rising Parkinsons Cases
More than1 million people in the U.S.live with Parkinsons disease, and that number is increasing as the population ages. Early detection using simple blood tests can help doctors take action before serious damage occurs.
- Move Toward Non-Invasive Testing
Unlike brain scans or neurological tests, blood-based diagnostics areeasier, quicker, and safer. They dont require expensive imaging machines or invasive procedures, making them more accessible for patients and doctors.
- Advances in Technology
New research toolslikegenomics, proteomics, andAI-powered diagnosticsare helping scientists discover and validate better blood-based indicators (biomarkers) for Parkinsons.
- Strong Support from Funders
Organizations like theNational Institutes of Health (NIH)and theMichael J. Fox Foundationare pouring money into research and testing to bring new diagnostic tools to the market faster.
- Push for Personalized Medicine
Doctors want totailor treatmentsto individual patients. Biomarkers help them do just thatidentifying who might benefit from specific therapies or who may respond better to certain drugs.
Explore The Complete Comprehensive Report Here:
Key Challenges
- Tough Regulatory Approval
To get FDA approval, these tests must be shown to besafe, effective, and reliable, which takes time and rigorous testing.
- High Development Costs
Its expensive to turn a scientific discovery into a usable clinical test. Smaller companies may struggle to compete due to the high costs of research and validation.
- Slow Clinical Adoption
Doctors and hospitals still rely on traditional diagnostic tools. Until biomarker-based tests are fully accepted and reimbursed by insurers, growth may be slower in the early years.
Market Breakdown
By Biomarker Type
- Alpha-synuclein Most studied and promising biomarker for Parkinsons.
- NfL (Neurofilament Light Chain) Useful for tracking disease progression.
- DJ-1 Protein,Inflammatory Markers, and othergenetic/metabolic indicatorsare also being explored.
By Application
- Early Diagnosis Currently the largest segment.
- Monitoring Progression
- Drug Trials & Development Fastest growing use case.
- Patient Selection for Treatment
By End User
- Hospitals & Clinics
- Diagnostic Labs
- Biotech & Pharma Companies Big users for drug research and development.
- Universities & Research Centers
Top Companies in the Market
|
Company |
Focus |
|
Abbott |
Blood-based testing platforms |
|
Alamar Biosciences |
High-sensitivity proteomics |
|
Amprion |
Detects misfolded alpha-synuclein |
|
Biogen |
Using biomarkers in drug research |
|
C2N Diagnostics |
Expanding from Alzheimers to Parkinsons |
|
Denali Therapeutics |
Developing biomarker-driven therapies |
|
Quanterix |
Leading ultra-sensitive testing tools |
|
SomaLogic |
Broad biomarker profiling |
|
Thermo Fisher |
Lab equipment and reagents |
|
Verily |
AI + multi-omics diagnostics |
Recent Milestones
- Apr 2024:Quanterix launched a new blood test panel combining three biomarkers in one.
- Feb 2024:Amprion got funding to expand long-term Parkinsons trials.
- Dec 2023:Denali started testing LRRK2-based blood biomarkers in a new treatment study.
- Oct 2023:SomaLogic partnered with a neurology network to validate tests in real-world clinics.
Looking Ahead
? Companion Diagnostics
Blood biomarkers will be used alongside drugs to guide treatmenthelping decide who gets what drug and when.
? AI and Big Data
Machine learning is making sense of complex biomarker data, improving test accuracy and speeding up new discoveries.
? At-Home and Point-of-Care Testing
Soon, patients may be able to take these testsoutside the clinicin pharmacies or even at homeoffering wider reach.
? Better Insurance and Policy Support
Clearer FDA guidelines and reimbursement policies will help doctors and labs adopt these tests faster.
Conclusion
TheU.S. blood-based biomarkermarketfor Parkinsons disease is growing fast and has the potential tochange how the disease is detected and managed. With strong support from funders, researchers, and biotech companies, the market is expected toreach over USD 1.1 billion by 2034.
Companies that invest inreliable testing platforms, secureregulatory approvals, and buildreal-world partnershipswill be best positioned to lead in this exciting and important healthcare space.
More Trending Latest Reports By Polaris Market Research:
Subcutaneous Drug Delivery Devices Market
Oncology companion diagnostic market
Non-Thermal Pasteurization Market
Induced Pluripotent Stem Cell (Ipsc) Market
Quality Management Software (Qms) Market
